Once-Daily Atomoxetine Treatment for Children and Adolescents With Attention Deficit Hyperactivity Disorder: A Randomized, Placebo-Controlled Study

By D. Michelson, Albert J. Allen, J. Busner, C. Casat, D. Dunn, C. Kratochvil, Jeffrey H. Newcorn, F. Sallee, R. Sangal, K. Saylor and 5 more. 2002

594 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Attention-Deficit/Hyperactivity Disorder in Adults (2004, background): “The first type of drug, atomoxetine, has an effect on norepinephrine systems alone [39,40].”
Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. (2007, background): “Michelson et al. (2002) showed that although atomoxetine was superior to placebo at week 1 of the trial, the greatest effects were observed at week 6, suggesting the patient should be maintained at the full therapeutic dose for at least several weeks to obtain the drug’s full effect.”
Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents (2019, unknown): “140 Authors of other reports suggest that more than 90% of patients will have a bene ﬁ cial response to 1 of the psychostimulants if a range of medications from both the methylphenidate and amphetamine and/or dextroamphetamine classes”